CAR NK biotech Cata­ma­ran Bio to wind down, will seek part­ners for cell ther­a­pies

Off-the-shelf cell ther­a­py biotech Cata­ma­ran Bio made a “re­cent de­ci­sion to com­mence wind-down,” CEO Alvin Shih told End­points News in an email on Mon­day.

The Boston biotech will cease day-to-day op­er­a­tions and seek strate­gic part­ners for its CAR NK cell ther­a­py can­di­dates and tech­nol­o­gy, Shih wrote in a LinkedIn post on Mon­day. Cata­ma­ran had 19 em­ploy­ees as of Mon­day morn­ing, he told End­points, and a “hand­ful” will stay on for a tran­si­tion pe­ri­od.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER